Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: An international, 6-week double-blind study

Lepine, J. P.; Altamura, C.; ANSSEAU, Marc; Ayuso Gutierrez, Jose Luis; Bitter, Istvan; Lader, Malcolm; Waintraub, Lionel

doi:10.1002/hup.289

Article (Scientific journals)

Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: An international, 6-week double-blind study

Lepine, J. P.; Altamura, C.; ANSSEAU, Marc et al.

2001 • In Human Psychopharmacology, 16 (3), p. 219-227

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/261351

DOI
10.1002/hup.289

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression.pdf

Author postprint (340.67 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Anxious symptoms; Major depressive disorder; Paroxetine; Tianeptine

Abstract :

[en] Tianeptine (37.5 mg/day) and paroxetine (20 mg/day) were compared in a population of depressive patients without past or current history of co-morbid anxiety and/or important anxiolytic treatment. In a 6-week, double blind trial, the special focus was on anxious symptoms. Both drugs showed good efficacy on depressive symptomatology, assessed with MADRS and HDRS, but no difference was detected between tianeptine and paroxetine, for any assessment criterion. Despite the choice of selected depressive patients, without any co-morbid anxious disorder, anxiety scale scores at inclusion (HAMA and BAS) were appreciable but correlated poorly with depressive scores. Both tianeptine and paroxetine improved the apparent anxious component in depression. Tolerability of both drugs was good, although significantly better with tianeptine. Thus tianeptine and paroxetine are effective and safe treatments for major depression and may also act directly on the anxious component of the psychopathology.

Disciplines :

Treatment & clinical psychology

Author, co-author :

Lepine, J. P.; Service de Psychiatrie, Hpital Fernand Widal, 200, rue du Faubourg St Denis, 75745 Paris Cedex 10, France

Altamura, C.; Service de Psychiatrie, Hpital Fernand Widal, 200, rue du Faubourg St Denis, 75745 Paris Cedex 10, France

ANSSEAU, Marc ; Université de Liège - ULg

Ayuso Gutierrez, Jose Luis; Servicio de Psiquiatria, Hospital Clinico de San Carlos - Madrid

Bitter, Istvan; Department of Psychiatry and Psychotherapy, Semmelweis Orvostudomanyi Egyetem - Budapest

Lader, Malcolm; Clinical Pharmacology Section, lnstitute of Psychiatry, Decrespigny Park, Denmark Hill - London

Waintraub, Lionel; Service de Psychiatrie, Centre Hospitalier Paul Brousse - Villejuif

Language :

English

Title :

Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: An international, 6-week double-blind study

Publication date :

2001

Journal title :

Human Psychopharmacology

ISSN :

0885-6222

eISSN :

1099-1077

Publisher :

John Wiley & Sons, Hoboken, United States - New Jersey

Volume :

Issue :

Pages :

219-227

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 24 June 2021

Statistics

Number of views

38 (1 by ULiège)

Number of downloads

425 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Alby J.M., Cabane J., Ferreri M., Bougerol T. (1993) Efficacy and tolerability of tianeptine in major depressive disorder and in dysthymia (DSM III R) with somatic complaints: Double blind study versus fluoxetine. Eur Neuropsychopharmacol 3(3):333.
Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association (4th edn). American Psychiatric Association: Washington, DC; 1994.
Andreasen N.C., Grove W.M., Maurer R. (1980) Cluster analysis and the classification of depression. Br J Psychiatry 137:256-265.
de Bonis M., Lebeaux M.O., de Boeck P., Simon M., Pichot P. (1991) Measuring the severity of depression through a self-report inventory. A comparison of logistic, factorial and implicit models. J Affect Disord 22:55-64.
Boulenger J.P., Fournier M., Rosales D., Lavallée Y.-J. (1997) Mixed anxiety and depression: From theory to practice. J Clin Psychiatry 58:27-34.
Boyer W.F., Feighner J.P. (1992) An overview of paroxetine. J Clin Psychiatry 53:3-6.
Cassano G.B., Heinze G., Loo H., Mendlewicz J., Paes de Sousa M. (1996) A double-blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes. Eur Psychiatry 11:254-259.
Clark L.A., Watson D. (1991) Tripartite model of anxiety and depression: Psychometric evidence and taxonomic implications. J Abnorm Psychol 100(3):316-336.
Costa e Silva J.A., Ruschel S., Caetano D. (1997) Placebo-controlled study of tianeptine in major depressive episodes. Neuropsychobiology 35:24-29.
Dalery J., Dagens-Lafont V., de Bodinat C. (2001) Efficacy of tianeptine vs placebo in the long term treatment (16.5 months) of unipolar major recurrent depression. Hum Psychopharmacol: Clin Exp 16:S39-S47.
Fawcett J. (1997) The detection and consequences of anxiety in clinical depression. J Clin Psychiatry 58:35-40.
Foster R.H., Goa K.L. (1997) Paroxetine. A review of its pharmacology and therapeutic potential in the management of Panic Disorder. CNS Drugs 8:163-188.
Guelfi J.D., Pichot P., Dreyfus J.F. (1989) Efficacy of tianeptine in anxious-depressed patients: Results of a controlled multicenter trial versus amitriptyline. Neuropsychobiology 22:41-48.
Hamilton M. (1989) Frequency of symptoms in melancholia (depressive illness). Br J Psychiatry 154:201-206.
Joffe R.T., Bagby M., Levitt A. (1993) Anxious and nonanxious depression. Am J Psychiatry 150:1257-1258.
Kessler R.C., Nelson C.B., McGonagle K.A. (1996) Comorbidity of DSM-III-R depressive disorder in the general population: Results from the US National Comorbidity Survey. Br J Psychiatry 168 17-30.
Kravitz H.M., Fogg L., Fawcett J., Edwards J. (1989) Antidepressant or antianxiety? A study of the efficacy of antidepressant medication. Psychiatry Res 32:141-149.
Kuhs H. (1991) Anxiety in depressive disorders. Compr Psychiatry 32:217-228.
Lépine J.P. (1994) Comorbidité des troubles anxieux et dépressifs: Perspectives épidémiologiques. Encéphale 20:683-692.
Lôo H., Malka R., Defrance R. (1988) Tianeptine and amitriptyline: Controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology 19:79-85.
Lôo H., Saiz-Ruiz J., Costa e Silva J.A. (1999) Efficay and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J Affect Disord 56:109-118.
Maier W., Falkai P. (1999) The epidemiology of comorbidity between depression, anxiety disorders and somatic diseases. Int Clin Psychopharmacol 14:S1-S6.
Martinsen E.W., Friis S., Hoffart A. (1989) A factor analytical study of the comprehensive psychopathological rating scale among patients with anxiety and depressive disorders. Acta Psychiatr Scand 80:492-498.
Riskind J.H., Beck A.T., Brown G., Steer R.A. (1987) Taking the measure of anxiety and depression. Validity of the reconstructed Hamilton scales. J Nerv Ment Dis 175(8):474-479.
Sartorius N., Üstün T.B., Lecrubier Y. (1996) Depression comorbid with anxiety: Results from the WHO study on psychological disorders in primary health care. Br J Psychiatry 168:38-43.
Watson D., Clark L.A., Weber K., Assenheimer J.S., Strauss M.E., McCormick R.A. (1995) Testing a tripartite model. I. Evaluating the convergent and discriminant validity of anxiety and depression symptom scales. J Abnorm Psychol 104:3-14.
Watson D., Clark L.A., Weber K., Assenheimer J.S. (1995) Testing a tripartite model. II. Exploring the symptom structure of anxiety and depression in student, adult, and patient samples. J Abnorm Psychol 104(1):15-25.
Wetzler S., Katz M.M. (1989) Problems with the differentiation of anxiety and depression. J Psychiatr Res 23:1-12.
Wittchen H.U., Schuster P., Lieb R. (2001) Comorbidity and mixed anxiety-depressive disorder (MAD): Clinical curiosity or pathophysiological need?. Hum Psychopharmacol: Clin Exp 16:S21-S30.
Wittchen H.U., Zhao S., Kessler R.C., Eaton W.W. (1994) DSM-III-R generalized anxiety disorder in the national comorbidity survey. Arch Gen Psychiatry 51:355-364.
1993.